ST Elevation Myocardial Infarction

MONDAY, March 31, 2025 -- For patients with out-of-hospital cardiac arrest (OHCA), the proportion receiving layperson bystander life support (BLS) has increased, but a critical factor in determining survival and long-term outcomes is how quickly cardiopulmonary resuscitation (CPR) is initiated, according to a study presented at the annual ESC Acute CardioVascular Care congress, held from March 14 to 15 in Florence, Italy. Aneta Aleksova, M.D., from the University of Trieste in Italy, and colleagues examined whether the percentage of layperson initial rescuers has changed over time in the setting of OHCA during ST-elevation myocardial infarction (STEMI). Data were included for 172 patients with OHCA among 3,315 with STEMI admitted in Italy between 2003 and 2024. The researchers found that 26 percent of the patients with OHCA were initially rescued by a layperson. The percentage of layperson BLS increased constantly, from 26 percent in 2003-2007 to 69 percent in 2020-2024. The median time to return of spontaneous circulation (ROSC) was 10 minutes. Compared with emergency medical service (EMS) CPR, longer ROSC was seen with layperson-initiated BLS (20 versus 5 minutes). Patients who received layperson BLS more frequently underwent endotracheal intubation than those receiving EMS CPR (91 versus 65 percent). Overall, 44 patients died during their hospital stay, with no difference seen by type of initial rescuer. On logistic regression analysis and after correction for rescuer type, predictors of in-hospital mortality included worse left ventricular ejection fraction, longer time to ROSC, and older age (odds ratios, 1.38, 1.38, and 1.46, respectively). Long-term outcome did not differ according to initial rescuer. "Our data highlights the importance of immediate resuscitation and underlines the importance to promote population awareness and BLS training to further improve survival after OHCA," the authors write. Press Release More Information Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Impella heart pump upgraded to Class 2a in ACC/AHA treatment guideline for cardiogenic shock secondary to STEMI DANVERS, Mass., March 27, 2025 /PRNewswire/ -- Johnson & Johnson MedTech, the global leader in heart recovery, will feature the latest evidence demonstrating the survival benefit of Impella® heart pump technology at the American College of Cardiology's 74th Annual Scientific Sessions & Expo (ACC.25), taking place in Chicago from March 29-31, 2025. Last month, the ACC and the American Heart Association (AHA) updated their guideline for the treatment of acute coronary syndrome (ACS), upgrading Impella from Class 2b to Class 2a due to Impella's proven ability to increase survival in patients with cardiogenic shock secondary to ST-segment elevation myocardial infarction (STEMI). The guideline update states it is reasonable to specifically use Impella in this patient population and that its survival benefit outweighs the risk. Several ACC sessions and presentations will focus on how providers are adapting to implement guideline-informed care based on the recommendations to enable better patient outcomes. Impella, the world's smallest heart pump, is inserted into the heart to temporarily take over the heart's pumping function, allowing the heart to rest and recover while maintaining the flow of oxygenated blood throughout the body. This therapy allows patients to return to their life and families with their native heart and experience an equal – or improved – quality of life. ACC/AHA Updated Guideline The guideline upgrade for Impella (Impella CP®) is based on evidence from the DanGer Shock RCT, which was published in the New England Journal of Medicine1 and presented at ACC.24. DanGer Shock is the first acute myocardial infarction cardiogenic shock (AMICS) trial to achieve its primary survival endpoint and showed a 26% overall relative risk reduction with a number needed to treat of 8 (p-0.04)2 in patients treated with Impella compared to the control arm. Since the data was released last year, multiple DanGer Shock sub analyses have been published, providing important details about the data: A Journal of the American College of Cardiology study demonstrates that patients under 77 years of age experience an even greater effect with an NNT of 5 (p=0.001).3 A JAMA Cardiology study shows that Impella reversed shock-related lactic acidosis significantly faster than controls and reduces the dependency on vasoactive drugs.4 "The DanGer Shock RCT results provide the highest level of scientific evidence demonstrating that Impella CP increases survival in patients with cardiogenic shock secondary to STEMI, which led the ACC/AHA to update their acute coronary syndrome treatment guideline within a year of the data being released," says Chuck Simonton, MD, Executive Vice President and Chief Medical Officer, Heart Recovery, Johnson & Johnson MedTech. "We will continue working with healthcare professionals to ensure that they are equipped with the training and clinical support necessary to implement guideline-informed care in their institutions, which will allow more patients to achieve heart recovery." Additional subanalyses show that adverse events in the DanGer Shock RCT are transient, including that bleeding was not associated with an impact on survival5 and no patients requiring temporary dialysis remained on dialysis at six months.6 Previous studies have demonstrated that STEMI-related cardiogenic shock patient outcomes can be further optimized with the use of Impella best practices, including a 2023 Japanese Percutaneous Ventricular Assist Device (J-PVAD) publication.7 Learning Opportunities for Healthcare Professionals The Johnson & Johnson booth at ACC.25 (#11013) will feature opportunities for healthcare providers to learn more about the updated treatment guideline for STEMI and cardiogenic shock and training and educational resources will be available. Additionally, there will be hands on case-based simulation sessions on best practices in Impella patient management moderated by leading healthcare provider experts in the Critical Care Sim Zone. There will also be a CME skills tent, "Lonely Nights in the ICU," which will be led by ACC faculty and will include a presentation on mechanical circulatory support. Sessions of Interest At ACC25, there will be live sessions, poster presentations and panel discussions focused on the latest advancements in treating heart disease patients with Impella, including cardiogenic shock and heart failure. Below are a few examples; click here to see a full list (with details on timing and locations): A Little Less Conversation, A Little More Action: SCAI Staging System of Cardiogenic Shock - Roy S. Gardner, MD All Shock Up: Diagnosing Cardiogenic Shock Profiles - Anju Bhardwaj, MD Impella for All? Lessons Learned from DanGer Shock and More! - Marwan Jumean, MD Putting it All Together: Cardiogenic Shock Management in 2025 - Shashank S. Sinha, MD DanGer Shock: One Year Later What Have We Learned? - Jacob E. Møller, MD Has DanGer Moved the Needle: Are More Trials Needed? - Judith S. Hochman, MD Overview of Modern MCS (Durable and Temporary) - Joyce W. Wald, MD About Cardiovascular Solutions from Johnson & Johnson MedTech Across Johnson & Johnson, we are tackling the world's most complex and pervasive health challenges. Through a cardiovascular portfolio that provides healthcare professionals with advanced mapping and navigation, miniaturized tech, and precise ablation we are addressing conditions with significant unmet needs such as heart failure, coronary artery disease, stroke, and atrial fibrillation. We are the global leaders in heart recovery, circulatory restoration and the treatment of heart rhythm disorders, as well as an emerging leader in neurovascular care, committed to taking on two of the leading causes of death worldwide in heart failure and stroke. For more, visit and follow us on LinkedIn and @jjmt_heartrecov. About Johnson & Johnson At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more about our MedTech sector's global scale and deep expertise in cardiovascular, orthopaedics, surgery and vision solutions at . Follow us at @JNJMedTech and on LinkedIn. ABIOMED, Inc. is part of Johnson & Johnson MedTech. Cautions Concerning Forward-Looking Statements This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding the Impella Platform. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of ABIOMED, Inc. and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: uncertainty of regulatory approvals; uncertainty of commercial success; challenges to patents; competition, including technological advances, new products and patents attained by competitors; product efficacy or safety concerns resulting in product recalls or regulatory action; changes to applicable laws and regulations, including global health care reforms; changes in behavior and spending patterns of purchasers of healthcare products and services; and trends toward healthcare cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's most recent Annual Report on Form 10-K, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at sec.gov, jnj.com or on request from Johnson & Johnson. Neither ABIOMED, Inc. nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments. _____________________________ 1 Møller, J., et al. (2024). Microaxial Flow Pump or Standard Care in Infarct-Related Cardiogenic Shock. N Engl J Med 2024;390:1382-1393. 2 Møller, J., et al. (2024). Microaxial Flow Pump or Standard Care in Infarct-Related Cardiogenic Shock. N Engl J Med 2024;390:1382-1393. 3 Klein, A., et al. (2024). Treating Older Patients in Cardiogenic Shock With a Microaxial Flow Pump: Is it DANGERous? J Am Coll Cardiol. 2025 Feb 18;85(6). 4 Udesen, NLJ., et al. (2024). Microaxial Flow Pump Hemodynamic and Metabolic Effects in Infarct-Related Cardiogenic Shock: A Substudy of the DanGer Shock Randomized Clinical Trial. JAMA Cardiol. 2025;10(1):9-16. 5 Holmvang, Lene. Impact of Bleeding Complications on Clinical Outcomes in Patients Undergoing Impella Support in Cardiogenic Shock (abstract) in: Transcatheter Cardiovascular Therapeutics (TCT) Conference; 2024 October 27-30; Washington, DC. 6 Zweck, E., et al. Microaxial Flow Pump Use and Renal Outcomes in Infarct-Related Cardiogenic Shock: A Secondary Analysis of the DanGer Shock Trial. Circulation (2024). Volume 150, Number 25. 7 Ikeda, Y., et al. (2023). Short-Term Outcomes of Impella Support in Japanese Patients With Cardiogenic Shock Due to Acute Myocardial Infarction - Japanese Registry for Percutaneous Ventricular Assist Device (J-PVAD). Circulation journal: official journal of the Japanese Circulation Society, 87(5), 588–597. Media Contact: Jenny Leary [email protected] Investor Contact: Tracy Menkowski [email protected] SOURCE Johnson & Johnson MedTech WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Roche’s Genentech unit has received approval from the US Food and Drug Administration (FDA) for TNKase (tenecteplase) in acute ischaemic stroke (AIS). The drug, which has been authorised for use in adults, is now the first stroke medicine to be approved by the regulator in almost three decades. Stroke is the fifth leading cause of death and the leading cause of long-term disability in the US, affecting more than 795,000 people every year. An AIS occurs when the blood supply to part of the brain is blocked or reduced, preventing brain tissue from receiving oxygen and nutrients. TNKase is a tissue plasminogen activator, clot-dissolving, thrombolytic medicine that starts a biochemical reaction that can break down fibrin, a component of blood clots. Until now, the only FDA-approved medicine for AIS was Roche/Genentech’s Activase (alteplase), which is administered as an intravenous (IV) bolus followed by a 60-minute infusion. TNKase, delivered as a single five-second IV bolus, offers a faster and simpler administration compared to Activase. The drug is also already approved in the US to treat acute ST-elevation myocardial infarction in adults. The FDA’s latest decision was supported by results from a large multi-centre non-inferiority study demonstrating that TNKase is comparable to Activase in AIS patients in terms of safety and efficacy. Levi Garraway, Genentech’s chief medical officer and head of global product development, said: “[This] approval is a significant step forward and underscores our commitment to advancing stroke treatment options for patients. “TNKase provides a faster and simpler administration, which can be critical for anyone who is dealing with an acute stroke.” The authorisation comes less than a month after the FDA approved a tablet formulation of Roche’s spinal muscular atrophy treatment Evrysdi (risdiplam). Evrysdi was originally authorised by the US regulator in 2020 to treat the progressive neuromuscular disease in patients aged two months and older, before being granted expanded approval in 2022 for infants aged under two months. It is hoped that the tablet formulation, which can either be swallowed whole or dispersed in water and stored at room temperature, will provide more freedom and independence over the original oral solution.